Key result
EPA supplementation and cardiac ANGPTL4 overexpression attenuate HFpEF progression and myocardial lipotoxicity in mice.
Why the study?
HFpEF has limited therapeutic options, and the specific contribution of imbalanced ω-6/ω-3 polyunsaturated fatty acids to myocardial lipid handling and HFpEF progression via the ANGPTL4/LPL signaling axis remained poorly understood.
Does targeting the ANGPTL4/LPL signaling axis via eicosapentaenoic acid (EPA) supplementation attenuate myocardial lipotoxicity and diastolic dysfunction in experimental models of HFpEF?
Does targeting the ANGPTL4/LPL signaling axis via eicosapentaenoic acid (EPA) supplementation attenuate myocardial lipotoxicity and diastolic dysfunction in experimental models of HFpEF?
Imbalanced ω-6/ω-3 fatty acid metabolism drives HFpEF progression via myocardial lipotoxicity, which can be mitigated by eicosapentaenoic acid (EPA) through activation of the cardioprotective ANGPTL4/LPL pathway.
Answers are grounded in this paper and cite their sources.
EPA supplementation merits clinical trials in HFpEF; leaves open whether ANGPTL4/LPL activation improves patient outcomes.
Background Heart failure with preserved ejection fraction (HFpEF) is a growing global burden with limited therapeutic options. While lipid metabolic disorders are hallmarks of HFpEF, the specific contribution of imbalanced -6/-3 polyunsaturated fatty acids (PUFAs) to myocardial lipid handling remains poorly understood. This study aims to elucidate how -6/-3 dysregulation drives HFpEF progression and to evaluate the therapeutic potential of targeting the ANGPTL4/LPL signaling axis. Methods Plasma fatty acid profiles were analyzed in HFpEF patients and healthy controls using targeted lipidomics. An in vivo HFpEF mouse model was established using a high-fat diet (HFD) combined with L-NAME to assess AAV9-mediated cardiac ANGPTL4 overexpression or knockdown. In vitro, neonatal rat cardiomyocytes (NRCMs) and H9c2 cells were treated with various fatty acids (palmitic acid (PA), oleic acid (OA), arachidonic acid (AA), and eicosapentaenoic acid (EPA)) under Angptl4 knockdown or overexpression to evaluate cell viability, lipid accumulation, and oxidative stress. Results (1) Clinical Lipidomics: HFpEF patients exhibited distinct lipidomic signatures, characterized by a significantly elevated -6/-3 ratio compared to controls. Notably, reduced plasma EPA levels were inversely correlated with the severity of clinical HFpEF phenotypes. (2) In Vivo Mechanisms: In HFpEF mice, myocardial Angptl4 expression was significantly upregulated alongside Lpl downregulation, indicating a compensatory but insufficient response to lipid overload. Cardiac-specific overexpression of ANGPTL4 significantly attenuated diastolic dysfunction, myocardial lipid accumulation and lipotoxicity. Conversely, Angptl4 knockdown exacerbated these pathological phenotypes, confirming its cardioprotective role. (3) In Vitro & Therapeutic Validation: Among the tested PUFAs, EPA demonstrated the most potent capacity to induce Angptl4 expression. Mechanistically, Angptl4 knockdown abolished the protective effects of EPA against oxidative stress and lipid accumulation. While EPA supplementation ameliorated HFpEF progression, these beneficial effects were largely abrogated in Angptl4-knockdown mice, confirming that EPA-mediated protection is dependent on the ANGPTL4/LPL axis. Conclusion Our findings reveal that imbalanced -6/-3 metabolism promotes HFpEF pathogenesis through myocardial lipotoxicity. EPA mitigates this injury specifically by activating the ANGPTL4/LPL pathway. Targeting this metabolic axis represents a promising nutritional and pharmacological strategy for HFpEF management.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question. Imbalanced ω-6/ω-3 PUFA ratios were elevated in HFpEF patients, while EPA supplementation and cardiac ANGPTL4 overexpression attenuated HFpEF progression and lipotoxicity in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: